跳转至内容
Merck

Y0001288

沙丁胺醇 半硫酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

α1-[(叔丁基氨基)甲基]-4-羟基-1,3-苯二甲醇 半硫酸盐, 硫酸舒喘灵

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H21NO3 · 0.5H2SO4
CAS号:
分子量:
288.35
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

albuterol, salbutamol

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

−20°C

SMILES 字串

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

InChI 密鑰

BNPSSFBOAGDEEL-UHFFFAOYSA-N

基因資訊

human ... ADRB2(154)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Salbutamol sulfate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

象形圖

Health hazardExclamation mark

訊號詞

Warning

危險聲明

危險分類

Carc. 2 - Repr. 2 - Skin Sens. 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

Helgo Magnussen et al.
The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)
Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.
Todd A Florin et al.
JAMA pediatrics, 168(7), 664-670 (2014-05-28)
Acute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there are no effective therapies available. Current evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronchiolitis. To determine whether nebulized
Susan Wu et al.
JAMA pediatrics, 168(7), 657-663 (2014-05-28)
Bronchiolitis is one of the most common and costly respiratory diseases in infants and young children. Previous studies have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency department (ED) setting is unclear. To compare
Dwight D Koeberl et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(5), 2171-2176 (2014-01-21)
Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased
B Padhukasahasram et al.
The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)
Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门